Citations

Clear

634 citation(s) found for "Hall, A".

Accuracy of the ABC/2 Score for Intracerebral Hemorrhage
Webb, Alastair J.S. , Ullman, Natalie , Morgan, Tim C., Muschelli, John , Kornbluth, Joshua , Awad, Issam A. , Rosenblum, Michael , Ziai, Wendy , Zuccarrello, Mario, Aldrich, François, John, Sayona , Harnof, Sagi , Lopez, George Α. , Broaddus, William C. , Wijman, Christine A.C., Vespa, Paul , Bullock, Ross, Haines, Stephen J. , Cruz‐Flores, Salvador , Tuhrim, Stan, Hill, Michael D. , Narayan, Raj K. , Hanley, Daniel F. , Tayal, Ashis , Díaz, Alberto Torres, Hoffer, Alan , Moheet, Asma , Agarwal, Sachin , Markowski, Mason, Rosenthal, Guy , Kureshi, Inam, Varelas, Panayiotis N. , Pinto, Pedro Telles Cougo, Camarata, Paul J. , Helms, Ann , Shahi, Kavian, Sinclair, David, Gizzi, Martin , LeDoux, David, Torbey, Michel , Cockroft, Kevin M. , Antezana, David, Margalit, Nevo, Crabtree, H. Mark, Lovick, Darren, Weaver, Michael, Leonardo, Jody, Ardelt, Agnieszka, Csiba, László , Wartenberg, Katja E. , Bösel, Julian , Adams, Harold P. , Hobohm, Carsten , Kerz, Thomas , Wechsler, Lawrence R. , Gardner, Paul A. , Decker, David A., Gonzales, Nicole R. , Caron, Jean-Louis, Hall, Christiana E., Ansari, Safdar , Luft, Andreas R. , Graham, R. Scott, Tucker, Kristi, Webb, Alastair Js , Mayo, Stephen L. , Martí‐Fábregas, Joan , Seder, David B. , Freeman, William D. , Lazaridis, Christos , LeDoux, David, Latorre, Julius Gene , Venkatasubramanian, Chitra , Jallo, Jack , Reinert, Michael , Butcher, Kenneth , Adeoye, Opeolu M , Testai, Fernando D. , Bulters, Diederik , Caron, Jean-Louis R., Arikán, Fuat , Hill, Michael D , Hanley, Daniel F , Lopez, George

Mayo Clinic

Stroke | August 5, 2015 | Volume: 46 | Issue: 9 | Pages: 2470-2476

10.1161/strokeaha.114.007343 | PMID 26243227 Get It

Background and Purpose— The ABC/2 score estimates intracerebral hemorrhage (ICH) volume, yet validations have been limited by small samples and inappropriate outcome measures. We determined accuracy of the ABC/2 score calculated at a specialized reading center (RC-ABC) or local site (site-ABC) versus the reference-standard computed tomography–based planimetry (CTP). Methods— In Minimally Invasive Surgery Plus Recombinant Tissue-Type Plasminogen Activator for Intracerebral Hemorrhage Evacuation-II (MISTIE-II), Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR-IVH) and CLEAR-III trials. ICH volume was prospectively calculated by CTP, RC-ABC, and site-ABC. Agreement between CTP and ABC/2 was defined as an absolute difference up to 5 mL and relative difference within 20%. Determinants of ABC/2 accuracy were assessed by logistic regression. Results— In 4369 scans from 507 patients, CTP was more strongly correlated with RC-ABC ( r 2 =0.93) than with site-ABC ( r 2 =0.87). Although RC-ABC overestimated CTP-based volume on average (RC-ABC, 15.2 cm 3 ; CTP, 12.7 cm3), agreement was reasonable when categorized into mild, moderate, and severe ICH (κ=0.75; P <0.001). This was consistent with overestimation of ICH volume in 6 of 8 previous studies. Agreement with CTP was greater for RC-ABC (84% within 5 mL; 48% of scans within 20%) than for site-ABC (81% within 5 mL; 41% within 20%). RC-ABC had moderate accuracy for detecting ≥5 mL change in CTP volume between consecutive scans (sensitivity, 0.76; specificity, 0.86) and was more accurate with smaller ICH, thalamic hemorrhage, and homogeneous clots. Conclusions— ABC/2 scores at local or central sites are sufficiently accurate to categorize ICH volume and assess eligibility for the CLEAR-III and MISTIE III studies and moderately accurate for change in ICH volume. However, accuracy decreases with large, irregular, or lobar clots. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: MISTIE-II NCT00224770; CLEAR-III NCT00784134.
Medium‐Chain Acyl‐CoA Dehydrogenase Deficiency in Adulthood: A Potential Diagnosis in a Patient with Mental Status Changes Suspected of Drug Toxicity
Randall, Morgan H. , Rolf, Cristin M., Gibson, Stephanie Mayfield, Hall, Patricia , Rinaldo, Piero, Davis, Gregory J., Hall, Patricia L

Mayo Clinic

Journal of Forensic Sciences | July 31, 2015 | Volume: 60 | Issue: 4 | Pages: 1101-1103

10.1111/1556-4029.12808 | PMID 26223762 Get It

AbstractMedium‐chain acyl‐CoA dehydrogenase (MCAD) deficiency is a rare but important component of the differential diagnosis for adults with a history of premortem mental status changes and the postmortem finding of hepatic steatosis. This case report describes a 30‐year‐old white man who, following a period of nausea and vomiting, was admitted to the hospital with sudden mental status deterioration followed rapidly by clinical deterioration and death. Treating physicians in this case suspected acute illicit drug toxicity with synthetic cathinones based on social history. Clinicians and medical examiners should be aware that the presentation, signs, and symptoms described may indicate an underlying inborn error of metabolism such as MCAD deficiency and take action accordingly.
Global and local ancestry in African‐Americans: Implications for Alzheimer's disease risk
Hohman, Timothy J. , Bailey, Jessica N. Cooke , Reitz, Christiane , Jun, Gyungah , Beecham, Gary W. , Carney, Regina M., Vance, Jeffery M. , Rajbhandary, Ruchita, Lin, Chiao‐Feng , Larson, Eric B., Graff‐Radford, Neill R. , Evans, Denis A., Jager, Philip L. De , Crane, Paul K. , Buxbaum, Joseph D. , Murrell, Jill R. , Raj, Towfique , Ertekin‐Taner, Nilüfer , Baldwin, Clinton T., Green, Robert C. , Barnes, Lisa L. , Cantwell, Laura B., Fallin, M. Daniele , Go, Rodney C.P., Griffith, Patrick , Obisesan, Thomas O. , Lunetta, Kathryn L. , Kamboh, M. Ilyas , Bennett, David A. , Hardy, John , Hendrie, Hugh C. , Hall, Kathleen, Goate, Alison , Lang, Rosalyn, Byrd, Goldie S. , Kukull, Walter A. , Farrer, Lindsay A. , Martin, Eden R. , Pericak‐Vance, Margaret A. , Schellenberg, Gerard D. , Mayeux, Richard , Haines, Jonathan L. , Thornton‐Wells, Tricia A., Carroll, Steven L. , Bennett, David A. , Naj, Adam Christian , Liu, Zhi , Cuccaro, Michael L. , Vardarajan, Badri Narayan , Wang, Weixin , Valladares, Otto , Logue, Mark W. , Manly, Jennifer J. , López, Oscar L. , Foroud, Tatiana , Seto, Mabel , Hardy, John , Goate, Alison M , Barnes, Lisa L

Mayo Clinic

Alzheimer's & Dementia | June 16, 2015 | Volume: 12 | Issue: 3 | Pages: 233-243

10.1016/j.jalz.2015.02.012 | PMID 26092349 Get It

AbstractIntroductionAfrican‐American (AA) individuals have a higher risk for late‐onset Alzheimer's disease (LOAD) than Americans of primarily European ancestry (EA). Recently, the largest genome‐wide association study in AAs to date confirmed that six of the Alzheimer's disease (AD)‐related genetic variants originally discovered in EA cohorts are also risk variants in AA; however, the risk attributable to many of the loci (e.g., APOE, ABCA7) differed substantially from previous studies in EA. There likely are risk variants of higher frequency in AAs that have not been discovered.MethodsWe performed a comprehensive analysis of genetically determined local and global ancestry in AAs with regard to LOAD status.ResultsCompared to controls, LOAD cases showed higher levels of African ancestry, both globally and at several LOAD relevant loci, which explained risk for AD beyond global differences.DiscussionExploratory post hoc analyses highlight regions with greatest differences in ancestry as potential candidate regions for future genetic analyses.
Biology‐Driven Gene‐Gene Interaction Analysis of Age‐Related Cataract in the eMERGE Network
Hall, Molly A. , Wallace, John R. , Lucas, Anastasia, Berg, Richard L. , Connolly, John J. , Crawford, Dana C. , Crosslin, David R. , Doheny, Kimberly F. , Haines, Jonathan L. , Harley, John B. , Jarvik, Gail P. , Kitchner, Terrie, Kuivaniemi, Helena , Larson, Eric B. , Tromp, Gerard , Vrabec, Tamara R. , Pendergrass, Sarah A. , McCarty, Catherine A. , Ritchie, Marylyn D. , de Andrade, Mariza, Verma, Shefali S. , Andrade, Mariza de , Carrell, David , Jarvik, Gail P , Connolly, John J

Mayo Clinic

Genetic Epidemiology | May 18, 2015 | Volume: 39 | Issue: 5 | Pages: 376-384

10.1002/gepi.21902 | PMID 25982363 Get It

ABSTRACTBioinformatics approaches to examine gene‐gene models provide a means to discover interactions between multiple genes that underlie complex disease. Extensive computational demands and adjusting for multiple testing make uncovering genetic interactions a challenge. Here, we address these issues using our knowledge‐driven filtering method, Biofilter, to identify putative single nucleotide polymorphism (SNP) interaction models for cataract susceptibility, thereby reducing the number of models for analysis. Models were evaluated in 3,377 European Americans (1,185 controls, 2,192 cases) from the Marshfield Clinic, a study site of the Electronic Medical Records and Genomics (eMERGE) Network, using logistic regression. All statistically significant models from the Marshfield Clinic were then evaluated in an independent dataset of 4,311 individuals (742 controls, 3,569 cases), using independent samples from additional study sites in the eMERGE Network: Mayo Clinic, Group Health/University of Washington, Vanderbilt University Medical Center, and Geisinger Health System. Eighty‐three SNP‐SNP models replicated in the independent dataset at likelihood ratio test P < 0.05. Among the most significant replicating models was rs12597188 (intron of CDH1)–rs11564445 (intron of CTNNB1). These genes are known to be involved in processes that include: cell‐to‐cell adhesion signaling, cell‐cell junction organization, and cell‐cell communication. Further Biofilter analysis of all replicating models revealed a number of common functions among the genes harboring the 83 replicating SNP‐SNP models, which included signal transduction and PI3K‐Akt signaling pathway. These findings demonstrate the utility of Biofilter as a biology‐driven method, applicable for any genome‐wide association study dataset.
The Role of Gabapentin in the Management of Alcohol Withdrawal and Dependence
Leung, Jonathan G. , Hall‐Flavin, Daniel K., Schmidt, Kristen A. , Schak, Kathryn M. , Hall-Flavin, Daniel, Nelson, Sarah E. , Leung, Jonathan G

Mayo Clinic

Annals of Pharmacotherapy | May 12, 2015 | Volume: 49 | Issue: 8 | Pages: 897-906

10.1177/1060028015585849 | PMID 25969570 Get It

Objective: To review the literature evaluating gabapentin for alcohol withdrawal and dependence. Data Sources: A literature search of MEDLINE (1966 to end of March 2015) and PubMed was performed using the terms alcohol, gabapentin, withdrawal, and dependence. Additional references were identified from a review of literature citations. Study Selection and Data Extraction: English-language prospective studies evaluating gabapentin for alcohol withdrawal and dependence were evaluated. Data Synthesis: A total of 10 publications utilizing gabapentin in alcohol withdrawal (n = 5) and alcohol dependence (n = 5) were included in this review. Limited data suggest that gabapentin can provide benefit in managing mild alcohol withdrawal syndrome. There were 5 reported or suspected seizures in the withdrawal studies, suggesting that additional safety data are necessary before gabapentin monotherapy can be routinely considered. Sleep and mood/anxiety-related outcomes were positively influenced by gabapentin, which may result in long-term benefits if continued beyond the withdrawal period for the treatment of alcohol dependence. Studies evaluating gabapentin for alcohol dependence demonstrated dose-dependent benefits for complete abstinence, rates of no heavy drinking, and cravings. Gabapentin used to treat alcohol dependence was well tolerated with no severe adverse reactions reported in the extant literature. Conclusion: Gabapentin may have a role in the treatment of mild alcohol withdrawal, but future studies should focus on adequate dosing strategies. Gabapentin should be considered for the treatment of alcohol dependence when barriers prevent the use of traditional agents. Additional studies should be conducted to further validate findings from the research conducted to date, but the current literature is promising for gabapentin in the treatment of alcohol dependence.
Abstract 38: Using molecularly characterized patient-derived models to delineate underlying drivers and vulnerabilities of epithelial ovarian cancer
Topp, Monique, Hartley, Lynne, Cook, Michele , Heong, Valerie , McShane, Lauren, Pyman, Jan, McNally, Orla , Ananda, Sumi, Harell, Maria I., Etemadmoghadam, Dariush , Galletta, Laura, Mitchell, Gillian, Kerr, Jeff B., Kaufmann, Scott H. , (AOCS), Australian Ovarian Cancer Study, Wakefield, Matthew M., Boehm, Emma , Alsop, Kathryn , Fox, Stephen B. , Hutt, Karla J. , (AOCS), Australian Ovarian Cancer Study, Swisher, Elizabeth M. , Bowtell, David D.L. , Wakefield, Matthew, Scott, Clare L. , Kaufmann, Scott H

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 23_Supplement | Pages: 38-38

10.1158/1538-7445.cansusc14-38 Get It

Abstract Background: Treatment options for women with ovarian cancer remain very limited and acquired resistance to current therapies is very common. Altered DNA repair capability in epithelial ovarian cancer (EOC) may underlie response to both standard therapy and novel treatments, such as PARP inhibitors. Molecular sub-classification of high-grade serous ovarian cancer (HG-SOC) may uncover potential drug targets and possible mechanisms of drug resistance. Understanding the contribution of DNA repair and other driver mutations to drug response and resistance requires the development of molecularly annotated preclinical models reflective of the clinic. Methods: A patient derived xenograft (PDX) cohort has been generated from consecutive, chemotherapy-naïve human HG-SOC and stratified according to in vivo response to standard chemotherapy, DNA repair capability and molecular characteristics, including next generation sequencing by Foundation Medicine. Resistance to therapy is driven by re-treating relapsed PDX in vivo providing invaluable “paired samples” (pre and post drug treatment), which are difficult to obtain from patients, to allow clonal evolution analysis of mechanisms of drug response and resistance. Results: The xenograft success rate was 83%. Of ten HG-SOC PDX, all exhibited mutations in TP53, five in BRCA1/2 (two of which were germline) and two were methylated for BRCA1. In vivo cisplatin response, determined as platinum sensitive (progression-free interval (PFI) ≥100 d, n=4), platinum resistant (PFI &lt;100 d, n=3) or platinum refractory (n=3), was largely consistent with patient outcome. Three of four platinum sensitive HG-SOC PDX contained DNA repair gene mutations, and the fourth was methylated for BRCA1. In contrast, all three platinum refractory PDX overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2). Molecular analysis of this cohort has revealed actionable targets for novel therapeutic strategies. In vivo studies, including with PARP inhibitors, are underway. Conclusion: PDX with histologic, molecular and therapeutic annotation, as well as clinical outcome data allow interrogation of molecular aberrations and drug resistance in vivo. This will inform targeting of novel therapies and the design of clinical trials for women. Citation Format: Monique D. Topp, Lynne Hartley, Michele Cook, Valerie Heong, Emma Boehm, Lauren McShane, Jan Pyman, Orla McNally, Sumi Ananda, Maria I. Harell, Dariush Etemadmoghadam, Laura Galletta, Kathryn Alsop, Gillian Mitchell, Stephen B. Fox, Jeff B. Kerr, Karla J. Hutt, Scott H. Kaufmann, Australian Ovarian Cancer Study (AOCS), Elizabeth M. Swisher, David D. Bowtell, Matthew M. Wakefield, Clare L. Scott. Using molecularly characterized patient-derived models to delineate underlying drivers and vulnerabilities of epithelial ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference: Cancer Susceptibility and Cancer Susceptibility Syndromes; Jan 29-Feb 1, 2014; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(23 Suppl):Abstract nr 38. doi:10.1158/1538-7445.CANSUSC14-38
The Flipped Classroom in Medical Education: Engaging Students to Build Competency
Hurtubise, Larry , Hall, Elissa , Sheridan, Leah B., Han, Heeyoung , Hurtubise, Larry

Mayo Clinic

Journal of Medical Education and Curricular Development | April 27, 2015 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/jmecd.s23895 | PMID 35187252 Get It

The flipped classroom represents an essential component in curricular reform. Technological advances enabling asynchronous and distributed learning are facilitating the movement to a competency-based paradigm in healthcare education. At its most basic level, flipping the classroom is the practice of assigning students didactic material, traditionally covered in lectures, to be learned before class while using face-to-face time for more engaging and active learning strategies. The development of more complex learning systems is creating new opportunities for learning across the continuum of medical education as well as interprofessional education. As medical educators engage in the process of successfully flipping a lecture, they gain new teaching perspectives, which are foundational to effectively engage in curricular reform. The purpose of this article is to build a pedagogical and technological understanding of the flipped classroom framework and to articulate strategies for implementing it in medical education to build competency.
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Stone, Jennifer , Thompson, Deborah J. , dos‐Santos‐Silva, Isabel , Lindström, Sara , Hazra, Aditi , Li, Jingmei , Eriksson, Louise , Jensen, Matt , Cunningham, Julie M. , Purrington, Kristen S. , Brown, Judith, Leyland, Jean, Warren, Ruth , Luben, Robert , Smith, Paula , Jud, Sebastian M. , Heusinger, Katharina, Beckmann, Matthias W. , Douglas, Julie A. , Shah, Kaanan P., Chan, Heang‐Ping , Helvie, Mark A. , Kolonel, Laurence N. , Woolcott, Christy , Haiman, Christopher A. , Giles, Graham G. , Baglietto, Laura , Krishnan, Kavitha , Southey, Melissa C. , Apicella, Carmel, Andrulis, Irene L. , Knight, Julia A. , Ursin, Giske , Alnæs, Grethe I.G., Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Simard, Jacques , Dunning, Alison M. , Easton, Douglas F. , Fasching, Peter A. , Vachon, Celine M. , Durocher, Francine , Cunningham, Julie, Scott, Christopher G. , Tamimi, Rulla M. , Kraft, Peter , Czene, Kamila , Hall, Per N , Olson, Janet E. , Couch, Fergus J. , Khaw, Kay‐Tee , Wareham, Nicholas J. , Marchand, Loı̈c Le , Maskarinec, Gertraud , Gram, Inger Torhild , Dennis, Joe , Pharoah, Paul D.P. , Pankratz, V. Shane , Hopper, John L. , Vachon, Celine M. , Luben, Robert N , Giles, Graham G , Southey, Melissa C , Dunning, Alison M , Li, Jingmei , Michailidou, Kyriaki , Simard, Jacques , Stone, Jennifer , Baglietto, Laura , Purrington, Kristen S , Chan, Heang-Ping

Mayo Clinic

Cancer Research | April 10, 2015 | Volume: 75 | Issue: 12 | Pages: 2457-2467

10.1158/0008-5472.can-14-2012 | PMID 25862352 Get It

Abstract Mammographic density measures adjusted for age and body mass index (BMI) are heritable predictors of breast cancer risk, but few mammographic density-associated genetic variants have been identified. Using data for 10,727 women from two international consortia, we estimated associations between 77 common breast cancer susceptibility variants and absolute dense area, percent dense area and absolute nondense area adjusted for study, age, and BMI using mixed linear modeling. We found strong support for established associations between rs10995190 (in the region of ZNF365), rs2046210 (ESR1), and rs3817198 (LSP1) and adjusted absolute and percent dense areas (all P &lt; 10−5). Of 41 recently discovered breast cancer susceptibility variants, associations were found between rs1432679 (EBF1), rs17817449 (MIR1972-2: FTO), rs12710696 (2p24.1), and rs3757318 (ESR1) and adjusted absolute and percent dense areas, respectively. There were associations between rs6001930 (MKL1) and both adjusted absolute dense and nondense areas, and between rs17356907 (NTN4) and adjusted absolute nondense area. Trends in all but two associations were consistent with those for breast cancer risk. Results suggested that 18% of breast cancer susceptibility variants were associated with at least one mammographic density measure. Genetic variants at multiple loci were associated with both breast cancer risk and the mammographic density measures. Further understanding of the underlying mechanisms at these loci could help identify etiologic pathways implicated in how mammographic density predicts breast cancer risk. Cancer Res; 75(12); 2457–67. ©2015 AACR.
Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population‐based study
Leibson, Cynthia L., Long, Kirsten Hall , Ransom, Jeanine E. , Roberts, Rosebud O., Hass, Steven , Duhig, Amy, Smith, Carin Y. , Emerson, Jane A., Petersen, Ronald C. , Pankratz, V. Shane , Smith, Carin Y

Mayo Clinic

Alzheimer's & Dementia | April 9, 2015 | Volume: 11 | Issue: 8 | Pages: 917-932

10.1016/j.jalz.2015.01.007 | PMID 25858682 Get It

Abstract Background Objective cost estimates and source of cost differences are needed across the spectrum of cognition, including cognitively normal (CN), mild cognitive impairment (MCI), newly discovered dementia, and prevalent dementia. Methods Subjects were a subset of the Mayo Clinic Study of Aging stratified‐random sampling of Olmsted County, MN, residents aged 70 to 89 years. A neurologist reviewed provider‐linked medical records to identify prevalent dementia (review date = index). Remaining subjects were invited to participate in prospective clinical/neuropsychological assessments; participants were categorized as CN, MCI, or newly discovered dementia (assessment date = index). Costs for medical services/procedures 1‐year pre‐index (excluding indirect and long‐term care costs) were estimated using line‐item provider‐linked administrative data. We estimated contributions of care‐delivery site and comorbid conditions (including and excluding neuropsychiatric diagnoses) to between‐category cost differences. Results Annual mean medical costs for CN, MCI, newly discovered dementia, and prevalent dementia were $6042, $6784, $9431, $11,678, respectively. Hospital inpatient costs contributed 70% of total costs for prevalent dementia and accounted for differences between CN and both prevalent and newly discovered dementia. Ambulatory costs accounted for differences between CN and MCI. Age‐, sex‐, education‐adjusted differences reached significance for CN versus newly discovered and prevalent dementia and for MCI versus prevalent dementia. After considering all comorbid diagnoses, between‐category differences were reduced (e.g., prevalent dementia minus MCI (from $4842 to $3575); newly discovered dementia minus CN (from $3578 to $711)). Following the exclusion of neuropsychiatric diagnoses from comorbidity adjustment, between‐category differences tended to revert to greater differences. Conclusions Cost estimates did not differ significantly between CN and MCI. Substantial differences between MCI and prevalent dementia reflected high inpatient costs for dementia and appear partly related to co‐occurring mental disorders. Such comparisons can help inform models aimed at identifying where, when, and for which individuals proposed interventions might be cost‐effective.
The association between sleep disturbances and alcohol relapse: A 12-month observational cohort study
Kolla, Bhanu Prakash , Schneekloth, Terry D. , Mansukhani, Meghna P. , Hall‐Flavin, Daniel K., Karpyak, Victor M. , Geske, Jennifer R. , Frye, Mark A. , Biernacka, Joanna M. , Kolla, Bhanuprakash , Mansukhani, Meghna P , Karpyak, Victor , Geske, Jennifer

Mayo Clinic

The American Journal on Addictions | March 24, 2015 | Volume: 24 | Issue: 4 | Pages: 362-367

10.1111/ajad.12199 | PMID 25808396 Get It